Join our daily newsletter At The Bell to receive exclusive market insights
- Dimerix (DX8) closes recruitment for its DMX-200 COVID-19 study, led by CLARITY 2.0, early so as to allow for more efficient analyses and reporting
- The company is trialling its DMX-200 product as a potential new treatment for respiratory complications associated with COVID-19
- Dimerix was initially planning to recruit 80 patients in India under the trial but has now capped off recruitment at 49 patients
- The safety and efficacy results of the clinical trial are currently being analysed by the CLARITY team and will be released to the ASX as soon as available
- Dimerix says it remains focused on its flagship program, the Phase 3 ACTION3 pivotal study of DMX-200 in focal segmental glomerulosclerosis (FSGS)
- Shares in Dimerix are trading grey at 15 cents at 1:35 pm AEST
Dimerix (DX8) has closed recruitment for its DMX-200 COVID-19 study, led by CLARITY 2.0, early so as to allow for more efficient analyses and reporting
The company is trialling its DMX-200 product as a potential new treatment for respiratory complications associated with COVID-19.
Dimerix initially planned to recruit 80 patients for the trial before conducting an interim safety analysis of the treatment. However, the company said it believed additional patient recruitment would not change the data outcomes relating to safety and efficacy, and as such, it closed recruitment after 49 patients.
CEO and Managing Director Nina Webster said the company was pleased to support the study using DMX-200 based on its “compelling mechanism of action and demonstrated safety profile”.
“With the recruitment now concluded, the current data can be assessed for positive signs of proof of concept,” Dr Webster said.
“If a positive signal is substantiated, Dimerix may then assess the next steps to progress towards the ultimate therapeutic outcome for these patients.
“With both COVID studies now under data review by the investigators, Dimerix continues to focus on our lead Phase Three focal segmental glomerulosclerosis (FSGS) program and further pipeline development.”
The results from the COVID-19 study will be analysed by the CLARITY team, which Dimerix will report on once it has received it.
Dimerix said it was still focusing on its flagship ACTION3 pivotal study of DMX-200 in FSGS, which is actively recruiting globally.
It is also focused on advancing its diabetic kidney disease program towards the next clinical study and planning the first clinical study for the DMX-700 chronic obstructive pulmonary disease (COPD) program.
Shares in Dimerix were trading grey at 15 cents at 1:35 pm AEST.
